BC Extra | Aug 26, 2019
Company News

With Celgene's $13.4B sale of Otezla, Amgen adds to anti-inflammatory franchise

Investors appeared to be more than satisfied with Celgene's take from the sale of Otezla to Amgen for $13.4 billion in cash, removing a hurdle from BMS's path toward the completion of its proposed $74...
BC Extra | Jun 25, 2019
Company News

Otezla divestiture makes next launches mission critical for BMS

The molecule that started Celgene's market decline, leading to its eventual takeout, is now being off-loaded to allow BMS to close the deal. Losing it from the line-up will raise the pressure for successful launches...
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
BC Week In Review | Oct 5, 2018
Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
BC Extra | Oct 1, 2018
Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
BC Extra | Jan 27, 2018
Company News

FDA to review its pediatric exclusivity decision for Amgen's Sensipar

A federal judge ordered FDA to address whether its decision to grant pediatric exclusivity to Ortho Tri-Cyclen norgestimate/ethinyl estradiol from the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) is consistent with its decision...
BC Week In Review | Nov 3, 2017
Clinical News

Biosimilar Orencia from Momenta and Mylan misses in PK trial

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) and Mylan N.V. (NASDAQ:MYL; Tel Aviv:MYL) said their proposed biosimilar of Orencia abatacept, M834, missed the primary pharmacokinetic endpoints compared to U.S.- and EU-sourced Orencia in a Phase I trial in...
BC Extra | Sep 12, 2017
Clinical News

AbbVie's upadacitinib meets in second Phase III for RA

AbbVie Inc. (NYSE: ABBV) said both doses of oral upadacitinib (ABT-494) met the two primary endpoints in the Phase III SELECT-BEYOND trial to treat moderate to severe rheumatoid arthritis. Upadacitinib is an oral Janus kinase-1...
BC Innovations | Aug 11, 2017
Strategy

The flip-side of immunotherapy

In the smaller print of last week’s deal between IFM Therapeutics Inc. and Bristol-Myers Squibb Co. was the latest example of a growing trend of companies aiming to draw extra value out of a cancer...
BC Week In Review | Jul 13, 2017
Clinical News

FDA approves Orencia for psoriatic arthritis

FDA approved Orencia abatacept from Bristol-Myers Squibb Co. (NYSE:BMY) to treat psoriatic arthritis. The product is a CTLA-4 (CD152)-Ig fusion protein available in both IV and subcutaneous formulations. It is already approved in the U.S....
Items per page:
1 - 10 of 222